[Influence of chronic pain in osteoarthritis on the risk of cardiovascular diseases and modern methods of drug prevention]. / Vliyanie khronicheskoi boli pri osteoartrite na risk razvitiya serdechno-sosudistykh zabolevanii i sovremennye sposoby ikh lekarstvennoi profilaktiki.

The purpose of the review of scientific medical literature was to evaluate the data of the epidemiology of osteoarthritis (OA) and cardiovascular diseases (CVD) with the analysis of risk factors, pathophysiological and pathobiochemical mechanisms of the relationship between OA and the risk of developing CVD in the presence of chronic pain, modern strategies for screening and management of this cohort of patients, the mechanism of action and pharmacological effects of chondroitin sulfate (CS). Conclusions were drawn about the need for additional clinical and observational studies of the efficacy and safety of the parenteral form of CS (Chondroguard) in patients with chronic pain in OA and CVD, improvement of clinical recommendations for the treatment of chronic pain in patients with OA and cardiovascular risk, with special attention to interventions that eliminate mobility restrictions in patients and the inclusion of basic and adjuvant therapy with DMOADs to achieve the goals of multipurpose monotherapy in patients with contraindications to standard therapy drugs.

[About the prognostic role of fibulin-5 protein in the progression of pathological vascular remodeling in patients with isolated sistolic arterial hypertension.]

Today, arterial hypertension (AH) is often associated with accelerated aging. In the structure of AH in persons over 65 years of age, the most common form is isolated systolic hypertension (ISAH), the mechanisms of development of which remain unexplained. Molecular regulation of remodeling of smooth muscle cells of vessels, changes in which, along with perivascular fibrosis and endothelial dysfunction, lead to increased sensitivity to procontractile mediators and calcification, forms the basis of mechanisms of vascular aging and rigidity. Clinically, this process is manifested in ISAH in individuals of an early period of old age and senile age. The search for new diagnostic molecular markers and the development of pharmacological correction of mechanisms of vascular wall aging in ISAH is an urgent and timely task. The review presents an analysis of current data from medical literature about the participation of fibulin-5 protein in the process of elastogenesis in the vascular wall, as well as in molecular pathological pathways of inflammation and aging of the vascular wall in ISAH. The role of multifunctional signal molecule fibulin-5 in the age-related loss of elasticity of the vascular wall is shown. Presented is the perspective of creating a drug from the group of senolitics based on fibulin-5 molecule, as well as modern application possibilities for preventing aging of the vascular wall of the drug Cytoflavin (active ingredients in 1 ml of solution: succinic acid, 100 mg; nicotinamide, 10 mg; riboxin, 20 mg riboflavin mononucleotide, 2 mg).

[The influence of citoflavin on molecular mechanisms of hypertensive encephalopathy development in patients with systolic arterial hypertension].

The molecular pharmacological effects of cytoflavin in patients with hypertensive encephalopathy (HE) and isolated systolic arterial hypertension (ISAH) have been investigated using the following methods: assessment of complaints, 24-hour arterial pressure monitoring, ultrasound diagnostics including echocardiography, measurement of lipid profiles and coagulograms, and molecular phenotyping by MALDI-TOF/TOF-MS. A combination of cytoflavin administration with standard therapy of HE and ISAH led to the most expressed return development of clinical symptoms, restoration of the hemodynamic, structural, and geometrical parameters of cardiovascular system, and normalization of the indices of lipid profiles and coagulograms in comparison to patients with HE and ISAH, which accepted only standard therapy. Molecular mechanisms of cytoflavin action have been revealed, which include control of the activity of cellular signaling pathways by means of intermolecular interactions. The optimized therapy of HE and ISAH is recommended for clinical application, which assumes a combined use of standard therapy and cytoflavin and provides a geroprotective action upon the cardiovascular system.

[The study of the effectiveness of drug prevention mechanisms of cardiovascular aging by cytoflavin].

The aim of the research was the search of the mechanism of Cytoflavin action in patients with isolated systolic arterial hypertension (ISAH) as the aging model. The following research methods were applied: the assessment of complaints, 24-hour arterial pressure monitoring, ultrasound diagnostic, volume sphygmography, lipid profiles and coagulogram, molecular phenotyping by MALDI-TOF-TOF-MS. The combination of Cytoflavin with standard therapy of ISAH led to the most expressed return development of clinical symptoms, the restoration of the haemodynamics, structural and geometrical parameters of cardiovascular system, indicators lipid profiles and coagulogram in the comparison with patients with ISAH, who accepted standard therapy and those of the control groups. Molecular mechanisms of Cytoflavin action, including regulation of the activity of cell signaling pathways through intermolecular interactions were found. We recommend using Cytoflavin together with the standard therapy in treatment of ISAH, which provides the action of geroprotectors for cardiovascular system.